Clinical trials center joins ProSciento’s program for NASH trial recruitment

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Klenger)
(Image: Getty/Klenger)

Related tags: Clinical trials, trial recruitment, Clinical research, NASH, CRO

High Point Clinical Trials Center is partnering with ProSciento to accelerate clinical trial recruitment of patients with NASH and NAFLD.

High Point Clinical Trials Center enters a three-year collaboration with ProSciento, a contract research organization (CRO) focused on metabolic diseases, as the center becomes a NASH PASS site partner.

The NASH PASS program from ProSciento matches sites with its proprietary methodology to improve enrollment outcomes in clinical trials for non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

Lorraine Rusch, president of HPCTC, told us that the center – which focuses on Phase I/II clinical proof of concept and translational medicine studies – was interested in the partnership because of the metrics-driven approach ProSciento uses as a means to drive faster recruitment of ”very valuable” patients in a quantitative manner. 

Through this partnership, HPCTC will use the NASH PASS protocol to identify individuals eligible for enrollment and contribute to the programs database of prospective clinical study participants evaluated for NAFLD and NASH studies. The center will use a combination of transient elastography (fibroscan), proprietary algorithms, and non-invasive biomarker testing, to determine enrollment eligibility.

In a statement, Rusch added: “These much-needed efforts will spur rapid recruitment of patients into clinical trials which directly translates into novel pharmaceutical products and new methodologies for earlier treatment of this emerging metabolic epidemic.”

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars